

Influenza and COVID-19 Surveillance graphs

UKHSA publishes a national influenza and COVID-19 surveillance report which summaries the information from the surveillance systems which are used to monitor influenza, COVID-19 and other seasonal respiratory viruses in England.

Additional figures based on these surveillance systems are included in this slide set.

The figures presented in this slide set are based on data from week 3 (between 15 January 2024 and 21 January 2024).




Contents

- 1) <u>Respiratory Datamart system (England)</u>
- 2) <u>Confirmed COVID-19 episodes in England</u>
- 3) <u>Second generation surveillance system (SGSS)</u>
- 4) <u>SARS-CoV-2 Whole Genome Sequencing (WGS) coverage, England</u>
- 5) <u>Community surveillance</u>
- 6) <u>Primary Care surveillance</u>
- 7) <u>Secondary Care surveillance</u>
- 8) <u>Co- and secondary infections in persons with COVID-19 and influenza in</u> <u>England</u>



Respiratory Datamart system (England)

Respiratory DataMart – influenza weekly positivity by UKHSA region



*Changes in positivity in London should be interpreted with caution as there was a low number of samples this week and is subject to retrospective updates


X)

UK Health

Security




Respiratory DataMart – Influenza subtypes



Please note y axis uses different scales across graphs




Respiratory DataMart – Respiratory syncytial virus (RSV) weekly positivity by UKHSA region



*Changes in positivity in London should be interpreted with caution as there was a low number of samples this week and is subject to retrospective updates




Respiratory DataMart – other respiratory viruses



Please note y axis uses different scales across graphs




Respiratory DataMart – other respiratory viruses



Please note y axis uses different scales across graphs



Respiratory DataMart – other respiratory viruses



Please note y axis uses different scales across graphs




Confirmed COVID-19 episodes in England



Data Information


- From the week 32 report onwards, case rates have been updated to use the latest ONS population estimates for mid-2020. Previously case rates were calculated using the mid-2019 population estimates
- From 11 January 2022 the requirement for <u>confirmatory PCR testing in individuals who test positive using a lateral flow device was</u> <u>temporarily removed</u>.
- Rates by ethnicity and IMD quantile will continue to be presented using the mid-2019 estimates, until the mid-2020 estimates become available.
- From 31 January 2022, UKHSA moved all COVID-19 case reporting in England to use a new episode-based definition which includes
 possible reinfections. Each infection episode is counted separately if there are at least 91 days between positive test results (PCR or
 LFD). Each infection episode begins with the earliest positive specimen date. Further information can be found on the <u>UK COVID-19</u>
 <u>dashboard</u>.
- Since 1 April 2022, free universal symptomatic and asymptomatic testing for the general public in England is no longer available, as outlined in the plan for <u>living with COVID-19</u>. As such, there will be a reduction in the reporting of data obtained through Pillar 2 from April 2022 onwards. Data in this report should be interpreted in the context of this change to testing. <u>Public health guidance</u> remains in place for cases and their close contacts. Additionally, further changes in <u>testing policy</u> are in effect since 1 April 2023, which may affect case rates and positivity rates.

UK Health Security Agency Seven-day rolling average PCR positivity (%) of confirmed COVID-19 cases tested by sex under Pillar 1




UK Health Security Agency

Weekly COVID-19 episodes tested under Pillar 1, per 100,000 population by age and UKHSA region, weeks 46 to 3



UK Health Security Agency


Weekly COVID-19 episodes tested under Pillar 1, per 100,000 population by ethnicity and GOR region, weeks 46 to 3



GOR stands for Government Offices for the Regions




Weekly COVID-19 rate tested under Pillar 1, per 100,000 population by IMD quintile (1 being the most deprived and 5 being the least deprived)





Second generation surveillance system (SGSS)

SGSS reported Influenza A cases by UKHSA region (all ages)




The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA region and over time, including short-term trends in testing. Therefore comparisons should be done with caution.

×.

UK Health

SGSS reported Influenza B cases by UKHSA region (all ages)




The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA regions and over time, including short-term trends in testing. Therefore comparisons should be done with caution.

X)

UK Health


UK Health Security Agency

SGSS reported RSV cases by UKHSA region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA region and over time, including short-term trends in testing. Therefore comparisons should be done with caution.

SGSS reported Adenovirus cases by UKHSA region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA region and over time, including short-term trends in testing. Therefore comparisons should be done with caution. 20


<u>koż</u>

UK Health

SGSS reported Parainfluenza cases by UKHSA region (all ages)


ŚŚ

UK Health



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA region and over time, including short-term trends in testing. Therefore comparisons should be done with caution. 21 25 January 2024

SGSS reported Rhinovirus cases by UKHSA region (all ages)




The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA region and over time, including short-term trends in testing. Therefore comparisons should be done with caution. 22

\$\$

UK Health

SGSS reported hMPV cases by UKHSA region (all ages)



The presented figures are based on laboratory reports through SGSS. Testing and reporting procedures vary by virus, UKHSA region and over time, including short-term trends in testing. Therefore comparisons should be done with caution. 23

Ś

UK Health

Security




SARS-CoV-2 Whole Genome Sequencing (WGS) coverage, England



SARS-CoV-2 coverage of sequencing with a valid result and genotyping over time

Last updated on 18 January 2024

Sequencing coverage of PCR positive tests



Grey shading was applied to the previous 14 days to account for reporting delays in sequencing data. Cases where the individual only tested using a lateral flow device are not included in the percentage denominator.




Community surveillance



Estimates of COVID-19 prevalence over time by age group between 14 November 2023 and 10 January 2024, Winter COVID-19 study, England

Last updated on 18 January 2024




95% credible interval




Estimates of COVID-19 prevalence over time by GOR region between 14 November 2023 and 10 January 2024, Winter COVID-19 study, England

Last updated on 18 January 2024





Number of acute respiratory infection outbreaks reported to UKHSA by type of educational setting, England





Primary Care surveillance



25 January 2024

UK Health Security Agency

General practice Influenza-like-illness consultation rates per 100,000 population, UK administrations

							V	Veek r	numbe	r						
GP ILI consultati on rates (all ages)	40	41	42	43	44	45	46	47	48	49	50	51	52	1	2	3
England (RCGP)	3.5	3.2	3.5	3.2	3.3	3.8	3.4	3.8	4.6	5.3	6.3	7.7	4.9	7.5	8.0	7.5
Wales	5.0	3.1	1.7	2.9	3.6	4.0	3.3	4.2	4.8	7.4	7.1	7.4	7.0	10.2	9.4	10.0
Scotland	1.5	0.7	2.7	2.6	1.9	7.0	2.3	4.3	4.7	4.2	3.8	7.1	6.8	16.7	7.1	9.4
Northern Ireland	3.3	3.2	3.6	3.4	2.9	4.2	3.7	3.7	4.2	6.5	7.0	9.3	8.7	14.9	16.4	17.4




Secondary Care surveillance



25 January 2024

UK Health Security Agency

Weekly COVID-19 hospitalisation rate per 100,000 trust catchment population by age group and UKHSA region, weeks 46 to 3





Rate of COVID-19 hospitalisation (to all levels of care including ICU-HDU) by ethnic group, per 100,000 ethnic group specific trust catchment population, England

100 trust catchment population -White - Asian 75 -Black Mixed 50 Other 25 0 May 2023 1112023 4042022 1112022 5892022 Jan 2023 Mar 2023 Month of admission

per 100,000 ethnic group specfic



Preceding, co- and secondary infections in persons with COVID-19 in England, Jul 2022 –8th Jan 2024

HCAI, Fungal, AMR, AMU & Sepsis Division



Preceding/co-/secondary infections with COVID-19

Background

- Numbers of preceding/co-/secondary infection remain low across UKHSA surveillance systems.
- Free community testing ended 31 March 2022 as part of the government's Living with COVID-19 plan, with asymptomatic testing continuing in some settings. As of 31 August 2022, asymptomatic testing in all settings, including hospitals, has been paused. Please use caution when comparing incidence of bacterial, fungal and viral preceding/co-/secondary infections with COVID-19 over time due to these differences in testing strategies.
- Published data analyses from pandemic wave 1 indicates increased mortality associated with COVID-19 and <u>influenza</u>, <u>key bacterial and fungal infections</u> and <u>invasive pneumococcal disease</u> (IPD) in comparison to persons without co/secondary infection.
- <u>Data analysis</u> from wave 1 indicates that *Aspergillosis* and *candidemia* cases had increased risk of mortality in comparison to patients without co/secondary infection.




Surveillance of bacterial, fungal and respiratory viral infections in persons with COVID-19 in England

Data information

- Data are provisional and subject to change due to possible delayed reporting of microbiological samples
- Relative undertesting for other pathogens may result in an underestimate of preceding/co-/secondary infection cases. In addition, testing varies between pathogens therefore caution should be used in comparing preceding/co-/secondary infection rates between different pathogens
- Preceding/co-/secondary infections refers to when a person has a COVID-19 infection with one or more other pathogen (Please see Appendix 1 – Preceding/co-/secondary infection definitions.)
 - Preceding infection: SARS-CoV-2 detected after another pathogen
 - Co-infection: SARS-CoV-2 and other pathogen detected at the same time
 - Secondary infection: SARS-CoV-2 detected before another pathogen
- The following outputs included in this section have been produced via the Unified Infection Dataset (UID)
- Bacterial, fungal and respiratory viral infection data sources:
 - Fungal, bacterial and respiratory viral data (excluding *Clostridioides difficile*): Second Generation Surveillance System (SGSS)
 - Respiratory viral data: Respiratory Datamart
 - Clostridioides difficile: HCAI Data Capture System

Last updated on UK Health Most frequent bacterial, fungal, and viral specimens, by timing of 11 January Security 2024 diagnosis, in persons with COVID-19 in England from ISO week 27 of Agency 2022



Key findings:

203

From ISO week 27 of 2022, the most frequent organisms identified were Escherichia coli, Influenza A, and Staphylococcus aureus.



Appendix 1: Pre-/co-/secondary infection definitions

The day pertains to the date of the sample collection that yielded a positive result. These definitions do not apply to persistent COVID-19 patients. Patients with persistent COVID-19 require independent clinical assessment.

Organism	Definition co-infection with SARS-CoV-2†	Definition of infection pre-SARS-CoV-2 infection (other pathogen is primary infection) or Definition of post SARS-CoV-2 secondary infection (SARS-CoV-2 is primary infection)				
Influenza A	+/- 1d	2-28d^				
Influenza B	+/- 1d	2-28d^				
RSV	+/- 1d	2-28d				
Adenovirus	+/- 1d	2-28d				
Enterovirus	+/- 1d	2-28d				
Human metapneumovirus	+/- 1d	2-28d				
Parainfluenza (any subtype)	+/- 1d	2-28d				
Seasonal coronavirus	+/- 1d *	2-28d				
Rhinovirus	+/- 1d	2-28d				
Co-infections in ECMO patient (patients w	ith most severe clinical respiratory signs)					
ECMO patients	Individual case review	Individual case review				
Blood stream and respiratory infections (b	acterial and fungal)					
Achromobacter xylosoxidans	+/- 1d	2-28d				
Acinetobacter spp.	+/- 1d	2-28d				
Aspergillus	+/- 1d	2-28d (pre) 2-60d (post, continually hospitalised patients only)				
Bordetella pertussis	+/- 28 d Culture/PCR (based on pertussis sample date) +/- 28 Serology/Oral fluid (anti-pertussis toxin Ig) (based on pertussis symptom onset date, excluding cases without onset date)	N/A (Pertussis presentation is often delayed)				
Burkholderia cepacia	+/- 1d	2-28d				
Candida spp.	+/- 1d	2-28d (pre) 2-60d (post, continually hospitalised patients only)				
Chlamydia pneumoniae	0-7d PCR	PCR within 14-28 d (8-13d PCR*)				
Enterobacter spp.	+/- 1d	2-28d				
Enterococcus spp.	+/- 1d	2-28d				
E. coli	+/- 1d	2-28d				
Haemophilus influenzae	+/- 2d	3-28d				

See final slide for †, ^ and * notes.

Continued overleaf



Appendix 1 continued: Pre-/co-/secondary infection definitions

Organism	Definition co-infection with SARS-CoV-2†	Definition of infection pre-SARS-CoV-2 infection (other pathogen is primary infection) or Definition of post SARS-CoV-2 secondary infection (SARS-CoV-2 is primary infection)						
Blood stream and respiratory infections (ba	acterial and fungal)							
Klebsiella spp.	+/- 1d	2-28d						
Legionella pneumophila/species	Individual case review	Individual case review						
Mycoplasma pneumoniae	0-7d PCR, IgM serology 0-21d <16y	PCR within 14-28 d (8-13d PCR*)						
Neisseria meningitidis	+/- 2d	3-28d						
Pseudomonas spp.	+/- 1d	2-28d						
Serratia spp.	+/- 1d	2-28d						
Staphylococcus aureus	+/- 1d	2-28d						
Coagulase-neg Staphylococcus (S. haemolyticus)	+/- 1d	2-28d						
Stenotrophomonas spp., (S. maltophilia)	+/- 1d	2-28d						
Streptococcus spp. ‡	+/- 1d	2-28d						
Streptococcus pneumoniae	+/- 2d	3-28d						
Tuberculosis								
Mycobacterium tuberculosis	Individual case review	Individual case review						
Pathogens of the immunocompromised (e	g HIV)							
HIV	Individual case review	Individual case review						
Gastrointestinal infections								
Listeria	0-5d *	Individual case review						
Campylobacter	0-5d *	Individual case review						
Shiga toxin-producing E. coli (STEC)	0-5d *	Individual case review						
Norovirus	0-5d *	Individual case review						
Salmonella	0-5d *	Individual case review						
Shigella	0-5d *	Individual case review						
Anaerobes								
C. difficile	+/- 1d	2-28d						
Bacteroides spp. (B. fragilis and non- fragilis Bacteroides)	+/- 1d	2-28d						

See final slide for †, * and **‡** notes.

Continued overleaf



Appendix 1 continued: Pre-/co-/secondary infection definitions

Notes

† From the first specimen date of a SARS-CoV-2 infection episode.

* Additional data check required. (Resistance is not detailed, data for MERS is not currently available).

^ Definition post- SARS-CoV-2 secondary infection (SARS-CoV-2 is primary infection). This has been extended from prior 14d secondary infection definition for influenza used by UKHSA to account for disparities in testing throughout the 28d period after SARS-CoV-2 detection.

‡ Streptococcus species includes the following groups and species:

Group	Species/other names					
Anginosus Group	Streptococcus anginosus; Streptococcus constellatus (Streptococcus constellatus subspecies constellatus Streptococcus					
	constellatus subspecies pharynges); Streptococcus Group F; Streptococcus intermedius; Streptococcus milleri group;					
	Streptococcus sinensis					
Bovis Group	Streptococcus alactolyticus; Streptococcus bovis untyped; Streptococcus equinus; Streptococcus gallolyticus subspecies					
	gallolyticus (Streptococcus bovis biotype I); Streptococcus infantarius (Streptococcus infantarius sp infantarius; Streptococcus					
	bovis biotype II); Streptococcus lutetiensis; Streptococcus infantarius subspecies coli (Streptococcus bovis biotype II);					
	Streptococcus pasteurianus (Streptococcus bovis biotype II)					
Closely Related Genera	Abiotrophia spp.; Aerococcus spp.; Faklamia spp.; Gemella spp.; Globicatella sanguinis; Granulicatella spp.; Leuconostoc					
	spp.; Pedicoccus spp.; Peptostreptococcus spp.					
Mitis Group	Streptococcus cristatus; Streptococcus mitior; Streptococcus mitis; Streptococcus oralis; Streptococcus pseudopneumoniae;					
	Streptococcus infantis; Streptococcus peroris					
Mutans Group	Streptococcus mutans; Streptococcus sobrinus					
Other streptococci (including but not	Anaerobic streptococcus; Streptococcus acidominimus; Streptococcus spp., other named/not fully identified; Streptococcus					
limited to)	suis; Streptococcus uberis					
Salivarius Group	Streptococcus vestibularis; Streptococcus thermophilus					
Sanguinis Group	Streptococcus gordonii; Streptococcus massiliensis; Streptococcus parasanguinis; Streptococcus sanguinis					
Streptococcus Group A	Group A; Streptococcus pyogenes; Streptococcus dysgalactiae subspecies equisimilis					
Streptococcus Group B	Group B; Streptococcus agalactiae					
Streptococcus Group C	Group C; Streptococcus dysgalactiae subspecies equisimilis; Streptococcus equi subspecies zooepidemicus					
Streptococcus Group G	Group G; Streptococcus canis; Streptococcus dysgalactiae subspecies equisimilis					